Is Relugolix a prescription drug?

Relugolix is a prescription drug that is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat adult patients with advanced prostate cancer. Regaglic is the first (and currently the only) oral GnRH receptor antagonist approved for the treatment of prostate cancer, for the symptomatic treatment of uterine fibroids and for the treatment of advanced prostate cancer.

Approximately56%of patients achieved castration-level testosterone concentrations (<50 ng/dL), and 97%of patients maintained this level during 48 weeks of treatment. Repagliflozneeds to be taken orally once daily to maintain desired testosterone concentrations. Androgen deprivation therapy may prolong the QTc interval and should be used with caution in patients who are at high baseline risk for QTc prolongation, such as those with electrolyte abnormalities, congestive heart failure, or other drugs known to prolong the QTc interval. Based on Repaglifloz's mechanism of action and animal study data, Repaglifloxacin may cause harm to the fetus if used in pregnant women-Male patients with female partners should be advised to use effective contraception throughout treatment and for 2 weeks after stopping treatment to prevent inadvertent exposure to the fetus. The protein binding rate of Regolicin plasma is 68-71%, and it is mainly bound to albumin and secondarily to α1-acidic glycoprotein. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.